In the first quarter of 2025, revenue recorded solid growth of +4.9% at constant exchange rates and scope ...

BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced ...

AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces the promotion of Donovan Quill to chief strategy officer, Life ...

Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today announced that the company’s abstract featuring clinical trial ...

Mr. Demurjian will participate in the panel discussion titled "The Good, the Bad and the Ugly: How to Approach Investors" scheduled for 8:05 - 8:50 a.m. PT on Friday, April 25. As CEO of Aspargo Labs ...

Dr. Young’s presentation, titled “Applying Principles of FDA’s Project Optimus to Oncology and Non-Oncology Rare Diseases,” will take place on Tuesday, April 24, 2025, at 2:00 p.m. Eastern Time at the ...

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the ...

REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers ...

We are thrilled to welcome Jessica to the RAPT leadership team at this pivotal time for the company,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT. “With her deep expertise as both an ...

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company (the “Common Share”) for the month of April 2025, ...

Liraglutide Offers Long-Term Stability and Expands Hydreight’s Comprehensive GLP-1 Weight Management Portfolio VANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) -- Hydreight ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort WATERTOWN, Mass., ...